Istraživači
Bila, Jelena
Godina
- 24 2020 - 2025
- 113 2010 - 2019
- 28 2000 - 2009
Mp-kat.
- 1 M70
- 1 остало
- < Prethodan
Godina - raspon
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
|---|---|---|---|---|
| 2023 | MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myeloma (✓) | Cook, Gordon; ...; Bila, Jelena S.   ; ...; (broj koautora 22) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2023 | Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy | Mateos, Maria-Victoria; Szarejko, Monika; Bila, Jelena S ; Schjesvold, Fredrik; Spicka, Ivan; Maisnar, Vladimir; Jurczyszyn, Artur; Grudeva-Popova, Zhanet; Hajek, Roman; Usenko, Hanna;
Thuresson, Marcus; Norin, Stefan; Jarefors, Sara; Richardson, Paul; Pour, Ludek;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2023 | Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial | Dimopoulos, Meletios Athanasios; ...; Bila, Jelena S ; ...; (broj, koautora 21) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2023 | The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings | Sretenovic, Aleksandra M; Mitrovic, Marko; Vukosavljevic, Nikola; Kecman, Natalija; Jovanovic, Jelica V; Bukumiric, Zoran M ; Bila, Jelena S | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2023 | Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network (✓) | Ludwig, Heinz; ...; Bila, Jelena S. ; ...; (broj koautora 29) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2022 | MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (✓) | Zamagni, Elena; ...; Bila, Jelena S. ; ...; (broj koautora 22) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2022 | Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial (✓) | Terpos, Evangelos; ...; Bila, Jelena S. ; ...; (broj koautora 23) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2022 | Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis - case report and literature review (✓) | Jovićević, Vanja; Bila, Jelena S. ; Mesaroš, Šarlota T. ; Pekmezović, Tatjana D ; Drulović, Jelena S. | Naučni članak | 23M23 - Rad u međ. časopisu |
| 2022 | Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study (✓) | Dimopoulos, Meletios A.; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena S. ;
Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Kampfenkel, Tobias; Liu, Weiping; Kosh, Michele; NamPhuong, Tran; Carson, Robin; Sonneveld, Pieter;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Ultra-high-risk prognostic significance of double and triple hit myeloma (✓) | Bila, Jelena S. ; Mitrović, Marko; Bukumirić, Zoran M. ; Jovanović, Jelica V.; Denčić-Fekete, Marija ; Sretenović, Aleksandra M.; Jeličić, Jelena J. ; Perić, Teodora; Mihaljević, Biljana S. ; Antić, Darko A. | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome (vol 105, pg 201, 2020) | Beksac, Meral; Seval, Guldane Cengiz; Kanellias, Nicholas; Coriu, Daniel; Rosinol, Laura; Ozet, Gulsum; Goranova-Marinova, Vesselina; Unal, Ali; Bila, Jelena S ; Ozsan, Hayri;
Ivanaj, Arben; Ibricevic-Balic, Lejla; Kastritis, Efstathios; Blade, Joan; Dimopoulos, Meletios Athanasios;
| Ostalo | Mp kategorija će biti prikazana naknadno. |
| 2021 | The implication and consequence of CD34+cell/subset quantity/ratio on the clinical outcome of hematologic malignancies treated by autologous stem cell transplants (✓) | Todorović, Milena R. ; Pavlović, Mirjana A.; Bila, Jelena S. ; Balint, Bela J. | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group (✓) | Bila, Jelena S. ; Katodritou, Eirini; Guenova, Margarita; Basic-Kinda, Sandra; Coriu, Daniel; Dapcevic, Milena; Ibricevic-Balic, Lejla; Ivanaj, Arben; Karanfilski, Oliver; Zver, Samo;
Beksac, Meral; Terpos, Evangelos; Dimopoulos, Meletios Athanassios;
| Naučni članak | 21M21 - Rad u vrhunskom međ. časopisu |
| 2021 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (✓) | Dimopoulos, Meletios Athanasios; ...; Bila, Jelena S. ; ...; (broj koautora 23) | Naučni članak | 21aM21a - Rad u međ. časopisu izuzetnih vrednosti |
| 2021 | Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study (✓) | Jagannath, Sundar; ...; Bila, Jelena S. ; ...; (broj koautora 45) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO (✓) | Terpos, Evangelos; ...; Bila, Jelena S. ; ...; (broj koautora 20) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Prognostic impact of response-adjusted ISS score in Multiple Myeloma (✓) | Mitrović, Marko; Bukumirić, Zoran M. ; Sretenović, Aleksandra M.; Miketić, Ivana; Bila, Jelena S. | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study (✓) | Sonneveld, Pieter; ...; Bila, Jelena S. ; ...; (broj koautora 21) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM) (✓) | Einsele, Hermann; ...; Bila, Jelena S. ; ...; (broj koautora 23) | Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2021 | Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases (✓) | Gerhardt, Kristin; ...; Sretenović, Aleksandra M.; ...; Todorović, Milena R. ; Bila, Jelena S. ; ...; Vučinić, Vladan | Naučni članak | 21M21 - Rad u vrhunskom međ. časopisu |